SEC Form SC 13G filed by Orthofix Medical Inc.

11/13/24 5:03:21 PM ET

Medical/Dental Instruments

Health Care

Get the next $OFIX alert in real time by email

SC 13G 1 ofix13gnov132024.txt SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 SCHEDULE 13G (Rule 13d-102) Orthofix Medical Inc. (Name of Issuer) Common Stock 68752M108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 68752M108 Page 2 of 4 Pages 1) Name of Reporting Person(s) I.R.S. Identification No. of Above Person (entities only) Paradigm Capital Management, Inc. 14-1770168 ----------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (a)_____ (b)_____ Not Applicable ----------------------------------------------------------------------------- 3) SEC Use Only ----------------------------------------------------------------------------- 4) Citizenship or Place of Organization New York ----------------------------------------------------------------------------- NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH (5) Sole Voting Power 2,556,500 (6) Shared Voting Power -0- (7) Sole Dispositive Power 2,556,500 (8) Shared Dispositive Power -0- ----------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,556,500 ----------------------------------------------------------------------------- 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable ----------------------------------------------------------------------------- 11) Percent of Class Represented by Amount In Row (9) 6.69% ----------------------------------------------------------------------------- 12) Type of Reporting Person IA ----------------------------------------------------------------------------- CUSIP NO. 68752M108 Page 3 of 4 Pages Item 1(a) Name of Issuer: Orthofix Medical Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 3451 Plano Parkway Lewisville, TX 75056 Item 2(a) Name of Person Filing: Paradigm Capital Management, Inc. Item 2(b) Address of Principal Business Office: Nine Elk Street, Albany, New York 12207 Item 2(c) Citizenship: A New York State Corporation Item 2(d) Title of Class of Securities: Common Stock Item 2(e) Cusip Number: 68752M108 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d- (b) or 9c), check whether the person filing is a: (e) [X] an investment adviser in accordance with 240.13d-1(b) (1)(ii)(E). Item 4. Ownership. (a) Amount beneficially owned: 2,556,500 (b) Percent of class: 6.69% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,556,500 (ii) Shared power to vote or direct the vote: -0- (iii) Sole power to dispose or to direct the disposition of: 2,556,500 (iv) Shared power to dispose or to direct the disposition of: -0- CUSIP NO. 68752M108 Page 4 of 4 Pages Item 5. Ownership of 5% or Less of a Class. If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of more than 5% on Behalf of Another Person. All securities reported in this Schedule 13G Report are owned by advisory clients of the Reporting Person. Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not Applicable Item 8 Identification and Classification of Members of the Group. Not Applicable Item 9 Notice of Dissolution of Group. Not Applicable Item 10. Certification. By signing below I (we) certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my (our) knowledge and belief, I (we) certify that the information set forth in this statement is true, complete and correct. Dated: November 13, 2024 PARADIGM CAPITAL MANAGEMENT, INC. By /s/ Gregg A. Miller Gregg A. Miller, Chief Compliance Officer Telephone: (518) 431-3500 - 4 -

Get the next $OFIX alert in real time by email

Recent Analyst Ratings for

$OFIX

Date	Price Target	Rating	Analyst
1/22/2025	$24.00	Buy	Canaccord Genuity
11/8/2024	$18.00 → $24.00	Hold → Buy	Stifel
5/8/2024	$15.00 → $20.00	Neutral → Buy	ROTH MKM
10/20/2023	$12.00	Neutral	ROTH MKM
9/12/2023		Buy → Neutral	BTIG Research
9/12/2023		Buy → Hold	Stifel
7/19/2023	$27.00	Buy	BTIG Research
3/4/2022	$41.00 → $45.00	Hold → Buy	Stifel

More analyst ratings

SEC Form SC 13G filed by Orthofix Medical Inc.

11/13/24 5:03:21 PM ET

$OFIX

Medical/Dental Instruments

Health Care

Get the next $OFIX alert in real time by email

Recent Analyst Ratings for

$OFIX

Date	Price Target	Rating	Analyst
1/22/2025	$24.00	Buy	Canaccord Genuity
11/8/2024	$18.00 → $24.00	Hold → Buy	Stifel
5/8/2024	$15.00 → $20.00	Neutral → Buy	ROTH MKM
10/20/2023	$12.00	Neutral	ROTH MKM
9/12/2023		Buy → Neutral	BTIG Research
9/12/2023		Buy → Hold	Stifel
7/19/2023	$27.00	Buy	BTIG Research
3/4/2022	$41.00 → $45.00	Hold → Buy	Stifel

More analyst ratings

SEC Form SC 13G filed by Orthofix Medical Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$OFIX

SEC Form SC 13G filed by Orthofix Medical Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$OFIX

$OFIX
Press Releases

Orthofix Reports Second Quarter 2025 Financial Results

Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference

Orthofix to Report Second Quarter 2025 Financial Results

$OFIX
Insider Purchases

Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

$OFIX
Insider Trading

President, Global Orthopedics Fisher Patrick sold $28,363 worth of shares (1,996 units at $14.21), decreasing direct ownership by 6% to 30,116 units (SEC Form 4)

Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

Director Finegan Michael was granted 26,087 shares, increasing direct ownership by 83% to 57,391 units (SEC Form 4)

$OFIX
SEC Filings

Amendment: SEC Form SCHEDULE 13D/A filed by Orthofix Medical Inc.

SEC Form 10-Q filed by Orthofix Medical Inc.

Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$OFIX
Analyst Ratings

Canaccord Genuity initiated coverage on Orthofix with a new price target

Orthofix upgraded by Stifel with a new price target

Orthofix upgraded by ROTH MKM with a new price target

$OFIX
Leadership Updates

Orthofix Announces Appointment of Vickie Capps to Board of Directors

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Orthofix Names Stephanie Walsh Chief Human Resources Officer

$OFIX
Financials

Orthofix Reports Second Quarter 2025 Financial Results

Orthofix to Report Second Quarter 2025 Financial Results

Orthofix Reports First Quarter 2025 Financial Results

$OFIX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.